Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Hemophilia B, Date of authorisation: 11/05/2016, Revision: 5, Status: Authorised

Case Medical Research ◽

10.31525/cmr-8e0202 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): NovoSeven, eptacog alfa (activated), Hemophilia B,Thrombasthenia,Factor VII Deficiency,Hemophilia A, Date of authorisation: 23/02/1996, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6ac70d ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Hemophilia B ◽

Assessment Report ◽

Factor Vii Deficiency ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Alprolix, eftrenonacog alfa, Hemophilia B, Date of authorisation: 12/05/2016, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-fcd084 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Alprolix, eftrenonacog alfa, Hemophilia B, Date of authorisation: 12/05/2016, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-fcb386 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Hemophilia B, Date of authorisation: 11/05/2016, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-8ecce9 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Nonafact, human coagulation factor IX, Hemophilia B, Date of authorisation: 03/07/2001, Revision: 9, Status: Withdrawn

Case Medical Research ◽

10.31525/cmr-29b43ac ◽

2020 ◽

Author(s):

Keyword(s):

Coagulation Factor ◽

Factor Ix ◽

Hemophilia B ◽

Assessment Report ◽

Coagulation Factor Ix ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rixubis, nonacog gamma, Hemophilia B, Date of authorisation: 19/12/2014, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-2249a9d ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): BeneFIX, nonacog alfa, Hemophilia B, Date of authorisation: 27/08/1997, Revision: 38, Status: Authorised

Case Medical Research ◽

10.31525/cmr-399687 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rixubis, nonacog gamma, Hemophilia B, Date of authorisation: 19/12/2014, Revision: 7, Status: Authorised

Case Medical Research ◽

10.31525/cmr-223e99a ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): NovoSeven, eptacog alfa (activated), Hemophilia B,Thrombasthenia,Factor VII Deficiency,Hemophilia A, Date of authorisation: 23/02/1996, Revision: 32, Status: Authorised

Case Medical Research ◽

10.31525/cmr-68b782 ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia A ◽

Hemophilia B ◽

Assessment Report ◽

Factor Vii Deficiency ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): BeneFIX, nonacog alfa, Hemophilia B, Date of authorisation: 27/08/1997, Revision: 38, Status: Authorised

Case Medical Research ◽

10.31525/cmr-91357b ◽

2019 ◽

Author(s):

Keyword(s):

Hemophilia B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text